Chemotherapy for advanced non-small cell lung cancer

Combined modality treatment for locally advanced non-small cell lung cancer: preoperative chemoradiation does not result in a poorer quality of life

“…Defining optimal treatment strategies for different subgroups of NSCLC patients is a challenge future research has to meet [28]. Aggressive treatment combinations with preoperative chemotherapy or bimodality induction might improve response rate and survival only for a small subset of patients which has yet to be identified [29].…”

Differential effects on lung cancer cell proliferation by agonists of glucocorticoid and PPARα receptors

“…The overall 5-yr survival rate among lung cancer patients is only about 15% [48,49]. The benefit of conventional therapies, such as chemotherapy and radiotherapy, for non-resectable late stage NSCLC patients is marginal with median survival time of 6-9 mo and the 1-yr survival of 25% [50,51]. Furthermore, the toxicity of chemotherapy and side-effects of radiotherapy can have severe repercussions on the quality of life of the patients, and are thus a major issue in cancer treatment.…”

The Utility of 2-Deoxy-2-[F-18]fluoro-d-glucose Positron Emission Tomography in the Investigation of Patients with Disseminated Carcinoma of Unknown Primary Origin

“…Treatment for both of these cancers has undergone a significant philosophical shift during the last five to ten years, with standard of care for young patients with a good performance status now being chemotherapy [19,20]. In the case of NSCLC, this is usually a combination of platinum with one newer drug, such as a taxane, vinorelbine, or gemcitabine [21,22]. In the case of pancreatic cancer, gemcitabine has become standard of care following a single, randomized trial in which patients receiving gemcitabine experienced an improvement in survival of 4.5 versus 5.5 months, an improvement in one-year survival, from 2% to 18%, and improved clinical benefit when compared to patients treated with weekly 5FU chemotherapy [20].…”